Abstract
Epidemiological studies in the past decade have stressed the importance of pulse pressure (PP) as an independent risk factor for cardiovascular morbidity and mortality. We briefly review the epidemiological evidence and discuss the patho-physiological mechanisms which involve arterial stiffness and wave reflections in older patients. We discuss the therapeutic consequences of targeting PP rather than systolic (S) or diastolic (D) blood pressure (BP) when using antihypertensive agents. With this line of evidence it is important, first, to determine what minimal PP level indicates cardiovascular risk and, second, to note that an increasing number of clinical studies indicate that PP is poorly sensitive to placebo, while SBP and DBP are conversely highly sensitive. Finally, on the basis of large-scale intervention trials, PP seems to be an appropriate tool for studies of clinical pharmacology and therapeutics in the fields of hypertension, congestive heart failure and other cardiovascular diseases.
Similar content being viewed by others
References
Safar ME, London GM. The arterial system in human hypertension. In: Swales JD, editor. Textbook of hypertension. London: Blackwell Scientific, 1994: 85–102
Franklin SS, Gustin IV W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation 1997; 96: 308–15
Pannier B, Brunei P, El Aroussy W, et al. Pulse pressure and echocardiographic findings in essential hypertension. J Hypertens 1989; 7: 127–32
Zanchetti A, Bond MG, Hennig M, et al. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens 1998; 16: 949–61
Safar ME. Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors. Curr Opin Nephrol Hypertens 2001; 10: 257–61
Darne B, Girerd X, Safar M, et al. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension 1989; 13: 392–400
Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease?: the Framingham Heart Study. Circulation 1999; 100: 354–60
Millar JA, Lever AF, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC mild hypertension trial. J Hypertens 1999; 17: 1065–72
Domanski M, Mitchell G, Pfeffer M, et al. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002; 287: 2677–83
Miura K, Dyer AR, Greenland P, et al. Pulse pressure compared with other blood pressure indexes in the prediction of 25-year cardiovascular and all-cause mortality rates: the Chicago Heart Association Detection Project in Industry Study. Hypertension 2001; 38: 232–7
Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke and total mortality: the Cardiovascular Health Study. Arch Intern Med 2001; 161: 1183–92
Blacher J, Gasowski J, Staessen JA, et al. Pulse pressure, not mean pressure, determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085–9
Benetos A, Zureik M, Morcet J, et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with high cardiovascular mortality. J Am Coll Cardiol 2000; 35: 673–80
Blacher J, Guerin A, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal failure. Circulation 1999; 99: 2434–9
Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause mortality in hypertensive patients. Hypertension 2001; 37: 1236–41
Meaume S, Rudnichi A, Lynch A, et al. Aortic pulse wave velocity, an independent marker of cardiovascular risk. J Hypertens 2001; 19: 871–7
Asmar R, Vol S, Brisac AM, et al. Reference values for clinic pulse pressure in a nonselected population. Am J Hypertens 2001; 14: 415–8
Verdecchia P, Schillaci G, Borgioni C, et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32: 983–8
Madhavan S, Ooi WL, Cohen H, et al. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395–401
Benetos A, Safar M, Rudnichi A, et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410–5
Benetos A, Rudnichi A, Safar M, et al. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998; 32: 560–4
Gerdts E, Papademetriou V, Palmieri V, et al. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocar-diographic left ventricular hypertrophy (the LIFE study). Am J Cardiol 2002; 89(4): 399–402
Harrington A. The placebo effect: an interdisciplinary exploration. Cambridge: Harvard University Press, 1997
Staessen JA, Thijs L, Clement D, et al. Ambulatory pressure decreases on long-term placebo treatment in older patients with isolated systolic hypertension. J Hypertens 1994; 12: 1035–9
Mancia G, Parati G, Ravogli A, et al. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995; 8: 311–5
Asmar R, Safar M, Queneau P. Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension. Am J Hypertens 2001; 14: 546–52
Safar ME, Myers MG, Leenen F, et al. Gender influence on the dose-ranging of a low-dose perindopril-indapamide combination in hypertension: effect on systolic and pulse pressure. J Hypertens 2002; 20: 1653–61
Asmar RG, Lacourciere Y, on behalf of the Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. J Hypertens 2000; 18: 1683–90
Staessen JA, Thijs L, O'Brien ET, et al. Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. Am J Hypertens 2002; 15: 835–43
Asmar R, Topouchian J, Pannier B, et al. Pulse wave velocity as end-point in large-scale intervention trials: the Complior study. J Hypertens 2001; 19: 813–8
Safar ME, Rudnichi A, Asmar R. Drug treatment of hypertension: the reduction of pulse pressure does not necessarily parallel that of systolic and diastolic BP. J Hypertens 2000; 18: 1159–63
Asmar RG, London GM, O'Rourke ME, et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension 2001; 38: 922–6
Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) sub-study. JAMA 2002; 288: 1491–8
Acknowledgements
The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Asmar, R., Safar, M.E. & Queneau, P. Pulse Pressure. Drugs 63, 927–932 (2003). https://doi.org/10.2165/00003495-200363100-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200363100-00001